Moreover, an FDA-approved combination of dabrafenib and trametinib administered in a molar ratio of 1:80 is routinely used for treatment of BRAF-mutated cancers as it is demonstrated to effectively enhance the inhibition of the BRAF pathway and increase survival of patients (18, 33). The gene discussed is BRAF; the disease is cancer.